medication Medication Safety Guide

Metformin needs an individual review. Some mitochondrial care guidance advises avoiding it as the first treatment because of acid buildup risk. A newer MIDD review considers monitored use in selected people. Your diabetes team should weigh your kidney and liver function, illness history and other options. Read the medication guide. Metformin recommendations differ: older mitochondrial consensus discourages first-line use because of lactic acidosis concerns, whereas a newer MIDD algorithm allows selected monitored use. Renal/hepatic function, acute illness and the evidence gaps inform the decision. Medication guide. ^{[3, 5]}

The sources do not all give the same advice. Older care recommendations discourage metformin first-line, while a newer MIDD review proposes selected monitored use. This uncertainty belongs in a discussion with your diabetes and mitochondrial teams. Older mitochondrial care consensus and newer MIDD treatment proposals differ on metformin. Direct MIDD comparative evidence remains limited; resolve use through individual specialist risk assessment. ^{[3, 5]}

Other diabetes medicines: your team may consider options such as DPP-4, GLP-1 or SGLT2 medicines. Evidence specifically in MIDD is limited, and weight, digestion and other risks matter. Other agents: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors have been proposed, largely using extrapolated evidence. Weight loss, gastrointestinal tolerance and ketoacidosis risk require individual assessment. ^{[5, 6]}

Valproate: it must not be used in POLG-related mitochondrial disease. In other mitochondrial conditions, specialists may consider it for seizures or mood disorders that have not responded to other treatments, only when there is no liver impairment and other safety requirements are met. Pregnancy and reproductive risks need a separate review. Do not stop prescribed treatment yourself. Valproate: contraindicated in POLG-related disease. The 2024 consensus allows consideration for refractory epilepsy or refractory mood disorders in non-POLG mitochondrial disease without liver impairment, subject to other contraindications and reproductive safety requirements. Specialist supervision is essential; avoid unsupervised withdrawal. ^{[2, 7]}

Medicine choices: several seizure medicines can be considered. A medicine being suitable for one person does not make it suitable for everyone. Selection: most antiseizure agents are not universally contraindicated in primary mitochondrial disease; treatment remains individualised. ^{[1, 2]}

Dichloroacetate (DCA) was tested as a way to lower lactate. A trial in people with m.3243A>G MELAS stopped early because of peripheral nerve damage, without demonstrating clinical benefit. It should not be used as a routine supplement or self-treatment. A randomised trial of DCA in m.3243A>G MELAS was terminated for peripheral neurotoxicity and did not demonstrate clinical benefit. It is not established routine therapy in this population. ^[8]

Tell the team about hearing loss and kidney problems before antibiotics. Gentamicin and related antibiotics can damage hearing. The best-established extreme genetic risk involves other mitochondrial variants, called MT-RNR1 variants. Your clinician should choose an antibiotic using the infection and your individual risks. Carry your care details. Aminoglycoside ototoxicity and nephrotoxicity warrant individual assessment. The particularly strong genotype-specific single-dose risk concerns MT-RNR1 variants, not m.3243A>G by itself. Antibiotic choice must account for infection severity, alternatives and baseline hearing/renal function. Emergency card. ^{[1, 3]}

Your clinician will consider other antibiotics where appropriate, but a serious infection may change the balance of risks. Tell the team about hearing loss, kidney disease and any additional genetic findings. Antibiotic selection should consider susceptibility, infection severity, alternatives, baseline auditory/renal function and relevant MT-RNR1 variants. ^{[1, 3]}